Concert An Alheimer's Disease Investigational Trial
Patients and Caregivers
Physcians
About dimebon
Join the Concert Study
1
Check if there is a study site in your area.
2
Check the study requirements.
Call toll-free
in the United States or
in the United Kingdom or
in Australia once you have completed steps 1 and 2.
About Dimebon
Dimebon (latrepirdine) is an investigational compound currently in Phase 3 development for the treatment of Alzheimer's disease (AD) and for Huntington's disease (HD).
In preclinical models of AD and HD explored thus far, dimebon (latrepirdine) has been shown to inhibit brain cell death, potentially by stabilizing and improving mitochondrial function in a way that prevents neuron death and dysfunction.
Other dimebon (latrepirdine) clinical trials
In a recent pivotal clinical trial of dimebon (latrepirdine) in patients with mild to moderate Alzheimer's disease, the following points were examined:
• 
Cognition and memory
• 
Activities of daily living
• 
Overall clinical function
• 
Behavioral problems
Based on the results of this recent study, the Connection Study is currently enrolling patients with mild to moderate Alzheimer's disease. The Connection Study is a global Phase 3, double-blind, placebo-controlled trial that will examine the efficacy and safety of dimebon (latrepirdine) in a large cohort of patients being treated in approximately 100 centers located in North America, South America, and Europe. Learn more about the Connection Study at www.CONNECTIONstudy.com.
Learn more about dimebon (latrepirdine) at Medivation.com.
Dimebon is an interim name.
The Concert Study is a Phase 3 trial sponsored by
Medivation, Inc, and Pfizer Inc.
Home  |  Terms of use  |  Privacy policy
Aricept® is a registered trademark of Eisai Co, Ltd.
© 2009 Medivation, Inc, and Pfizer Inc. All rights reserved.